Ildefonso Vicente-Suarez

Role: Earli
Location: San Jose, CA, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Ildefonso Vicente-Suarez

Immunologist by training with 20 years of scientific experience, eight of them in…

Experience

Earli
Present

Education

Universidad Complutense de Madrid
Bachelor, Biology
1994 — 2000
University of South Florida
Ph.D, Cancer Biology
2002 — 2007

Skills

Protein Chemistry
Rt-Pcr
Cell Culture
Transfection
Signal Transduction
Immunofluorescence
Cancer Research
Cell
Flow Cytometry
Cell Signaling
Facs
Elisa
Molecular Cloning
Animal Models
Western Blotting
Pcr
Molecular Biology
Fluorescence Microscopy
Immunology
Tissue Culture
Cell Biology
Immunoassays
Vaccines
Biochemistry
In Vitro
In Vivo
Immunohistochemistry
Qpcr

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@earli.com
Personal email
•••••@•••••.com
Direct dial
+16•••••••95

Unlock verified contacts

Free to start · No credit card required

Current company

Earli

Biotechnology Research · 36 employees · Founded 2018 · Redwood City, California, United States

Earli mission is to make cancer a benign experience by turning cancer against itself. Earli creates genetic constructs that turn on only in cancer cells and then re-program the cancer cells to produce their own therapies, to kill themselves. Earli has been funded by Andreessen Horowitz\'s a16z Bio+Health Fund, Khosla Ventures, Perceptive Advisors, Sands Capital, Marc Benioff, Menlo Ventures, Accenture Ventures, Han River Partners (S Korea). Earli is based in Redwood City, California. For decades, the vision has been dreamed about to one day “program disease cells to kill or cure themselves.” If disease cells could be taken control of, they could be forced to run “injected biologic programs” to attack themselves or activate the body’s immune system to fight the disease. Standing in the way is a fundamental unsolved questions in medicine: how to correctly distinguish healthy cells from disease cells. For cancer, many attempts have been made to “kill the bad cells while not killing the good ones.” The conventional approaches are still crude; they attack both cancers and patients, or don\'t produce any response at all. Earli turns the approach to targeting cancer cells on its head. Based on original research at Stanford University and subsequent 7 years of research at Earli, the company has built programmable genetic constructs that can infiltrate any cells but use conditional logic inside the cell nucleus to determine if a cell is a cancer cell, or not. The construct switches on only in cancer cells, then forcing them to become \"factories\" that produce encoded proteins that activate the immune system to attack and ultimately kill the cancer. In essence, the cancer cells are forced to produce their own therapies.

earli.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Ildefonso Vicente-Suarez

Experience

Education

Universidad Complutense de Madrid

University of South Florida

Skills

Find verified contacts for anyone on LinkedIn